A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Key facts

Sponsor

Prometic Biotherapeutics, Inc.

Principal Investigator

Amy Shapiro, MD

Indiana Hemophilia & Thrombosis Center

Intervention

Plasminogen (Human) intravenous(biological)

Enrollment

15 target

Eligibility

2-80 years · All sexes

Timeline

2016 – 2018

Study locations (2)

• Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
• Oslo University Hospital HF, Oslo, Sognsvannvejen 20, Norway

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hypoplasminogenemia

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT04275232
  Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis
  Dorothy Bautista, MD
• RECRUITINGNCT03797495
  Study of Individuals Affected With Hypoplasminogenemia
  Indiana Hemophilia &Thrombosis Center, Inc.

See all trials for Hypoplasminogenemia →